跳至主要内容
临床试验/NCT01066572
NCT01066572已完成1 期

Paramedic Initiated Lisinopril For Acute Stroke Treatment: a Pilot Randomised Controlled Trial

Newcastle-upon-Tyne Hospitals NHS Trust4 个研究点 分布在 1 个国家目标入组 14 人开始时间: 2010年10月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
已完成
发起方
入组人数
14
试验地点
4
主要终点
Number of participants enrolled per month

研究概览

简要总结

This study aims to investigate the use of lisinopril to lower blood pressure in stroke patients, pre-hospital, by research-trained paramedics.

详细描述

High blood pressure immediately following stroke is common and related to poorer stroke functional outcome and death. Although treatment of high blood pressure is well established for thre prevention of stroke, it is unclear if high blood pressure observed immediately after stroke should be lowered.

Several previous clinical trials have lowered blood pressure in acute stroke but this has not resulted in improved stroke outcome. One reason for this may be because treatment was started too late after stroke occurred. There is rapid progression of brain injury following stroke and any stroke treatment may need to be started very early to have a beneficial effect. Previous trials started blood pressure lowering after patients arrived at hospital and this was usually a significant time after stroke occurred.

The earliest time after stroke that blood pressure treatment could be started is during contact with the emergency medical services (paramedics). This research study is a pilot double blind randomised controlled trial of paramedic initiated blood pressure treatment for patients with high blood pressure immediately after stroke.

Patients with high blood pressure and suspected acute stroke will be identified and offered the opportunity to participate in the study by research trained paramedics from the North East Ambulance Service NHS Trust. Patients who agree to participate in the study will receive either lisinopril (a common blood pressure lowering medication) or 'dummy' (placebo) treatments for seven days. The first dose of medication will be given by the paramedic in the ambulance. Subsequent tablets will be given in hospital. The effects of treatment will be monitored by measuring blood pressure, neurological outcome and adverse events.

All aspects of study feasibility including recruitment rates and compliance with data collection will be recorded. The study will run for one year and recruit 60 patients.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
40 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Adults ≥ 40 years old
  • New unilateral arm weakness thought to be due to acute stroke within 3 hours of symptom onset
  • Hypertension as defined by systolic BP >160mm Hg on two consecutive seated or lying readings taken 5 - 10 minutes apart
  • Conscious (eyes open spontaneously ie "A" on Alert, Voice, Pain, Unresponsive (AVPU) scale)
  • Patient being transported to a PIL-FAST trial site (i.e. Royal Victoria Infirmary, North Tyneside General Hospital and Wansbeck General Hospital)
  • Verbal consent obtained from participant or next of kin
  • Exclusion criteria:
  • Age < 40 years
  • Females who are pregnant, lactating or at risk of pregnancy (i.e. who are not surgically sterile or at least 1 year post last menstrual period). Females < 56 years of age consented by a relative will be excluded as menstrual history may be unknown.
  • Any presentation of suspected stroke without unilateral arm weakness
  • Cannot establish that stroke onset time (i.e. when patient was last seen well without symptoms) was within the last 3 hours
  • Systolic BP < 160mm Hg
  • Reduced level of consciousness (below "A" on AVPU scale)
  • Patient not being transported to PIL-FAST trial site
  • Absence of participant or next of kin consent
  • Known to be taking ACE-inhibitor or Angiotensin II Receptor Blocker medication already
  • Known sensitivity to lisinopril or other ACE-inhibitor medication
  • Pulse > 120 beats per minute
  • Seizure activity in this illness episode (witnessed or history)
  • Hypoglycaemia (blood glucose < 3.5 mmols/l)
  • Cannot walk independently prior to stroke (walking stick / frame is allowed)
  • Obvious understanding or memory problems when next of kin is absent
  • Significant head trauma or brain surgery in the last 3 months
  • Known renal failure
  • Known liver failure (or currently jaundiced)
  • Uncontrolled heart failure (breathlessness at rest)
  • Receiving palliative care for known malignancy
  • Currently enrolled in a clinical trial assessing a study drug

排除标准

  • 未提供

研究组 & 干预措施

Lisinopril

Experimental

Experimental

干预措施: Lisinopril (Drug)

Placebo

Placebo Comparator

Placebo Comparator

干预措施: Placebo (Drug)

结局指标

主要结局

Number of participants enrolled per month

时间窗: 1 year

The primary outcome measure is the number of participants enrolled in the study per month.

次要结局

  • Additional time spent on scene(1 year)
  • Clinical outcome measures(1 year)
  • Proportion completing study medication(1 year)
  • Proportion fulfilling eligibility criteria(1 year)
  • Proportion enrolled by research trained paramedic(1 year)
  • Hospital staff compliance(1 year)
  • Proportion attended by research trained paramedic(1 year)
  • Proportion approached but not enrolled(1 year)
  • Paramedic compliance(1 year)
  • Adverse events(1 year)

研究者

发起方
Newcastle-upon-Tyne Hospitals NHS Trust
申办方类型
Other
责任方
Sponsor

研究点 (4)

Loading locations...

相似试验